Page   1/2   
  • Positioning for prosperity? Catching the next wave
    The Deloitte Growth 25 (DG25), identifies reasons to be optimistic about growth in Australia. Download the latest Building the Lucky Country report.
    Deloitte report, March 2014 | 102 pages
  • Adjusting to the new world of risk management
    Surveys 192 senior TMT, Life Sciences & Consumer/Industrial Products company executives on current risk management issues & practice.
    Deloitte/Forbes Insights Executive Survey, May 2012 I 20 pages
  • Investment in new technologies: CEO survey findings
    Covers past & projected use of R&D incentives & investment in new technologies in the manufacturing, construction & services sectors.
    Australian Industry Group/Deloitte CEO Survey, January 2012 | 26 pages
  • Chinese outbound M&A: Life Sciences & Health Care
    Five year review of greater China LSHC (and other sector) M&A activity plus future deal expectations drawing from mergermarket data.
    2011 Greater China M&A Spotlight, October 2011 | 72 pages
  • Key Findings in Global Consumer Survey
    This survey offers several important considerations for pharmaceutical, biotechnology, and medical device companies.
    Survey Report, June 2011 | 4 pages
  • 2011 Global Consumer Survey
    Regardless of the type of health care system, consumers globally are feeling the pinch of health care spending as a household expense.
    Survey and related materials, June 2011 | 40 pages
  • Robotic dispensing: automation in pharmacy
    Reviews the benefits which have been realised overseas (US /UK) and how Australian hospitals can leverage the lessons learnt.
    Deloitte perspective, October 2010 | 12 pages
  • Social networks: Real world applications to life sciences
    Covering research, clinical trial feasibility & recruitment, physician relations, compound identification & patient mobilisation.
    Deloitte US LSHC Report, July 2010 | 32 pages
  • Health technology assessment: involving consumers
    Identifies best practice HTA systems for managing the introduction, use and reimbursement of new technologies, including medicines.
    Deloitte Economics study for Eli Lilly, October 2009 | 89 pages
  • Social networks for life sciences
    This US report offers an in depth analysis of the current and future use of social networks in the life sciences industry.
    Report, July 2010 | 32 pages
  • Page   1/2